Even after accounting for belly fat loss, tesamorelin still increased paraspinal muscle density by 1.58 units in people with HIV and belly fat, showing a direct muscle effect.

For people with HIV and belly fat who responded to tesamorelin, the drug helped increase muscle density in their trunk muscles by 1.56 to 4.86 units compared to those who didn't take it.

For HIV patients with belly fat who responded to tesamorelin, the drug was linked to better muscle density in four trunk muscles, with improvements between 1.56 and 4.86 units compared to placebo after 26 weeks.

For HIV patients with belly fat who responded to this drug, taking tesamorelin for 6 months made their trunk muscles less fatty and more dense, like turning soft muscle into firmer muscle.

HIV patients with belly fat who responded to tesamorelin saw better lean muscle quality in their abdominal and rectus muscles, with improvements of 1.39 and 1.78 units respectively compared to placebo after 26 weeks.

Tesamorelin increased rectus and psoas muscle size by 0.44 and 0.46 cm² in people with HIV and belly fat, and this effect remained even after accounting for belly fat loss.